AIM
XLRN

Artemis Investment Management’s Acceleron Pharma XLRN Stock Holding History

Artemis Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,859
Closed -$1.36M – 331
2021
Q2 		$1.36M Buy
+10,859
New +$1.37M 0.01% 264

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artemis Investment Management's XLRN Position: Q3 2021 in Review

Artemis Investment Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 10,859 shares — an estimated $1.36M sold.

Artemis Investment Management first reported a position in XLRN in Q2 2021 and held it in 1 quarter. The position peaked at $1.36M in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Artemis Investment Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Artemis Investment Management sold 10,859 Acceleron Pharma shares in Q3 2021, an estimated $1.36M.
  • Artemis Investment Management first reported a position in Acceleron Pharma in Q2 2021 and held it in 1 quarter.
  • Artemis Investment Management's Acceleron Pharma position peaked at $1.36M in Q2 2021.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Artemis Investment Management's 13F filing for Q3 2021, filed 26 Oct 2021.